Name: Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test (Video) | JoVE Journal
Uploaded: 2016-11-13T13:00:00.000+00:00
Duration: 6 min 59 s
Description: Learn to perform intravenous glucose tolerance tests in macaques for metabolic disease research. This standardized protocol enables stratification of subjects by glycemic status to study insulin resistance and diabetes progression.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The authors would like to acknowledge the strong support of the DHMRI CLAS animal care staff, Facility Manager Mr. Daniel Peralta and attending veterinarian, Dr. Glicerio Ignacio, DVM MRCVS.

All animal procedures were approved by the David H. Murdock Research Institute IACUC located on the North Carolina Research Campus (NCRC), under protocol 14-017, Characterization of a nonhuman primate model of diabetes and prediabetes/insulin resistance and efficacy of therapeutics to improve insulin sensitivity and metabolic function.
1. Animal Selection and Study Preparation
<ol>
	<li>Select diet and weight stable animals based on monthly food intake and body weight records. 
	NOTE: Animals that have exhibited a recent decline in appetite should not be characterized until their food intake has stabilized.
	<ol>
		<li>For mature animals (&#62; 5 - 6 yr), do not select animals whose body weights between consecutive months differ by more than 10% without first examining the monkey and ruling out causes other than changing metabolic status for the dramatic change in weight.</li>
	</ol>
	</li>
	<li>For glucose, insulin and c-peptide analytes, prepare K2EDTA sample collection tubes with protease inhibitor (Aprotinin and DPP4I). 
	NOTE: The DPP4I + Aprotinin cocktail provides a broad spectrum of protease inhibition should this be required for additional analytes (glucagon, GLP-1). In the event that additional analytes are not collected, the blood tubes should be prepared in the same way to maintain consistency in sample collection. Samples for assays not validated for this method should be collected separately, according to the recommendations of the manufacturer.
	<ol>
		<li>Prepare the protease inhibitor cocktail by mixing 100 mg lyophilized Aprotinin with 10 ml of DPP4I. Add 10 &#181;l of the Aprotinin + DPP4I mixture to each blood tube for every milliliter of blood collected.</li>
		<li>Add an additional 10 &#181;l of the protease inhibitor cocktail to each tube for possible collection overage. Store the treated-blood tubes at -20 &#176;C until use. Keep the tubes on wet ice during the procedure and spin at 4 &#176;C.</li>
		<li>Use a serum separator tube to collect a blood sample at baseline for standard serum chemistry analysis. For the Complete Blood Cell count (CBC), use a standard K2EDTA without protease inhibitors. Use cryovials to aliquot plasma and serum after the blood samples have been spun down.</li>
		<li>Label the blood tubes and the cryovials appropriately with the animal identification, date, procedure, timepoint, and sample volume. Label the cryovials with the analyte(s) in plasma for appropriate assay.</li>
	</ol>
	</li>
	<li>Prepare the heparinized saline flush by injecting 0.15 ml of 1,000 USP units per ml heparin into a 250 ml bag of normal saline. Obtain a solution of 0.06 mg heparin/ml. Draw 40 - 60 ml of this solution into a saline lock for flushing between samples. Draw an additional 1 ml and 5 ml into separate syringes for flushing the dextrose infusion port before and after the infusion, respectively.</li>
</ol>
2. Animal Sedation and Preparation
<ol>
	<li>Remove food from the animal&#39;s cage no less than 14 hr before the procedure, and no more than 18 hr. 
	NOTE: It is important that animals be fasted for the procedure to avoid any post-prandial variation in glycemic values. It is also a precaution to avoid regurgitation and aspiration of stomach contents while anesthetized.</li>
	<li>Sedate animals for the duration of the IVGTT procedure with ketamine given intramuscularly as a general anesthetic, at 10 mg/kg. Administer additional ketamine (5 - 10 mg/kg) at intervals of 20 - 30 min, or as needed, during the procedure.
	<ol>
		<li>Weigh the sedated animal. Place the animal in a laterally recumbent position on a heated procedure table.</li>
		<li>Monitor clinical parameters every 15 to 20 min to ensure the animal is in a stable plane of anesthesia. Measure heart rate (100 - 200 bpm) and SPO2 (&#62; 92%) with a pulse oximeter. Measure respiratory rate (20 - 50 breaths/min) with a stopwatch, counting respirations visually or by hand over fifteen seconds and multiplying by four. Measure temperature (&#62; 97 &#176;F) rectally. Monitor the color of the mucous membrane around the gum and lips (moist, pink).</li>
	</ol>
	</li>
	<li>Prepare two cannula sites. Use hair clippers to trim the hair from the area of interest where the catheter will be inserted, and sterilize the entire region with alternating scrubs of chlorhexidine and 70% alcohol.
	<ol>
		<li>Place one catheter in the region of the left or right cephalic or saphenous veins and attach it to a heparin saline flush (0.06 mg heparin/ml) with a three-way stopcock. This is the sampling blood draw site.</li>
		<li>Place the second catheter in another leg or arm in the region of the cephalic or saphenous veins and attach a port. Use this site for the dextrose infusion. Use a small, 1 ml flush of heparinized saline to keep the cannula patent prior to dextrose infusion.</li>
	</ol>
	</li>
</ol>
3. IVGTT Procedure
NOTE: The IVGTT procedure consists of 8 blood draw sampling time-points (Table 1).
<ol>
	<li>Take the baseline sample and use a hand held glucometer to measure the fasting blood glucose level. Obtain a serum sample for standard chemistry analysis, as well as a whole blood sample for a CBC in order to assess the overall health of the animal. Collect plasma samples to assay glucose and insulin levels from the baseline sample using a kit validated for use with macaques as per the manufacturer&#39;s instructions 8, 9. 
	NOTE: It is important to have a pre-draw of 0.5 ml taken from the cannula prior to taking any sample for blood collection to remove residual blood or heparin in the dead-space of the cannula.</li>
	<li>After obtaining the baseline sample, infuse the dose of 50% dextrose (250 mg/kg) over 30 sec into the dextrose infusion port. 
	NOTE: Higher dose models (500 mg/kg) can be used, though the dose should be fixed across procedures in order to make longitudinal comparisons.
	<ol>
		<li>Flush the infusion port with 5 ml of heparinized saline to make sure that there is no dextrose left in the port. The end of the infusion is the T0. Have the technician replace the gloves, as residual dextrose from the infusion may contaminate subsequent blood samples.</li>
	</ol>
	</li>
	<li>The first post-infusion sample time point is at T3 min, from the end of dextrose infusion, followed by T5 min, T7 min, T10 min, T15 min, T20 min, and the last sample time point is at T30 min. Collect plasma from each timepoint to assay glucose and insulin levels with the baseline sample (see step 3.1).
	<ol>
		<li>At the T3 min time point, use the hand held glucometer to once again check the blood glucose level. 
		NOTE: The glucometer readings at baseline and T3 are only to confirm the infusion of the dextrose. The blood glucose level at the T3 min time point should be ~100 mg/dl higher compared to the fasting baseline plasma glucose level.</li>
	</ol>
	</li>
</ol>
4. Animal Recovery and Sample Processing
<ol>
	<li>Remove the cannulas and apply pressure to the catheterized sites for hemostasis after the T30 min time-point. Monitor the animal until it has regained consciousness and is sitting up. Offer feed once the animal is fully recovered.</li>
	<li>Immediately place each whole blood sample into K2EDTA tubes on ice. Centrifuge at 3,000 rpm at a temperature of 4 &#176;C within 10 min of collection. Aliquot plasma samples into cryovials, freeze and store at -80 &#176;C until analysis.
	<ol>
		<li>Allow the blood into the serum tube for standard serum chemistry analysis to sit at room temperature for no less than 20 min and no more than 30 min before centrifugation at 3,000 rpm at RT. Freeze the serum samples until assayed within 48 hr of collection. 
		NOTE: Refrigerate the whole blood samples collected for CBC analysis until assayed within 24 hr of collection.</li>
	</ol>
	</li>
</ol>
5. Data Treatment
<ol>
	<li>After establishing the plasma insulin and glucose curves, determine the glucose clearance rate K from the slope of the natural log of glucose values above baseline 16, 17. 
	NOTE: A healthy NHP may be expected to have a glucose clearance rate K well above 1, often greater than 2 or more, as a healthy animal will often return to their baseline glucose values within 30 min. As insulin production drops off, the glucose clearance rate K will drop more dramatically, falling below 1.</li>
	<li>Calculate the AUC as a whole, as the sum of totals of the area of the trapezoids representing the area under the curve of each line segment between time-points, through T30 16, 17. 
	NOTE: Traditionally, the AUC of the first ten minutes of the procedure is considered the acute insulin response to glucose (AIR), while the AUC from the last 20 min of the procedure is considered the late insulin response (LIR). As the animal becomes more dysmetabolic, the insulin AUC will increase, reflecting compensation for increasing insulin insensitivity. As the animal transitions to overt diabetes, however, the AUC will decrease, often initially in the acute insulin phase, captured by the AIR.</li>
</ol>

<ol><li>Bergman, R., Phillips, L., Cobelli, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Physiologic+evaluation+of+factors+controlling+glucose+tolerance+in+man%5BTitle%5D)+AND+%22J.+Clin.+Invest%22%5BJournal%5D)">Physiologic evaluation of factors controlling glucose tolerance in man.</a> J. Clin. Invest. 68, 1456-1457 (1981).</li>
<li>Bergman, R., Prager, R., Volund, A., Olefsky, J. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Equivalence+of+the+insulin+sensitivity+index+in+man+derived+by+the+minimal+model+and+the+euglycemic+glucose+clamp%5BTitle%5D)+AND+%22J.+Clin.+Invest%22%5BJournal%5D)">Equivalence of the insulin sensitivity index in man derived by the minimal model and the euglycemic glucose clamp.</a> J. Clin. Invest. 79, 790-800 (1987).</li>
<li>Hovorka, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Partitioning+glucose+distribution%2Ftransport%2C+disposal%2C+and+endogenous+production+during+IVGTT%5BTitle%5D)+AND+%22Am.+J.+Physiol.+Endocrinol.+Metab%22%5BJournal%5D)">Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT.</a> Am. J. Physiol. Endocrinol. Metab. 282, E992-E1007 (2002).</li>
<li>Salinari, S., Guidone, C., Bertuzzi, A., Manco, M., Asnaghi, S., Mingrone, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((First-phase+insulin+secretion+restoration+and+differential+response+to+glucose+load+depending+on+the+route+of+administration+in+type+2+diabetic+subjects+after+beriatric+surgery%5BTitle%5D)+AND+%22Diabetes+Care%22%5BJournal%5D)">First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after beriatric surgery.</a> Diabetes Care. 32 (3), 375-380 (2009).</li>
<li><a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=%22Clinical+Diabetes+Research%3A+Methods+and+Techniques%22">Clinical Diabetes Research: Methods and Techniques</a>. Roden, M. , John Wiley & Sons. (2007).</li>
<li>Cobelli, C., Pacini, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Insulin+secretion+and+hepatic+extraction+in+humans+by+minimal+modeling+of+c-peptide+and+insulin+kinetics%5BTitle%5D)+AND+%22Diabetes%22%5BJournal%5D)">Insulin secretion and hepatic extraction in humans by minimal modeling of c-peptide and insulin kinetics.</a> Diabetes. 37, 223-231 (1988).</li>
<li>Lorenzo, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Disposition+index%2C+glucose+effectiveness%2C+and+conversion+to+type+2+diabetes%3A+the+insulin+resistance+atherosclerosis+study%5BTitle%5D)+AND+%22Diabetes+Care%22%5BJournal%5D)">Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the insulin resistance atherosclerosis study.</a> Diabetes Care. 33, 2098-2103 (2010).</li>
<li>Hansen, B. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Investigation+and+treatment+of+type+2+diabetes+in+nonhuman+primates%5BTitle%5D)+AND+%22Methods+Mol+Biol%22%5BJournal%5D)">Investigation and treatment of type 2 diabetes in nonhuman primates.</a> Methods Mol Biol. 933, 177-185 (2012).</li>
<li>Hansen, B. C., Bodkin, N. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Standardization+of+IVGTT.+Importance+of+method+used+to+calculate+glucose+disappearance%5BTitle%5D)+AND+%22Diabetes+Care%22%5BJournal%5D)">Standardization of IVGTT. Importance of method used to calculate glucose disappearance.</a> Diabetes Care. 16 (5), 847(1993).</li>
<li>Hardwood, J. H., Listrani, P., Wagner, J. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nonhuman+primates+and+other+animal+models+in+diabetes+research%5BTitle%5D)+AND+%22J+Diabetes+Sci+Tech%22%5BJournal%5D)">Nonhuman primates and other animal models in diabetes research.</a> J Diabetes Sci Tech. 3, 503-514 (2012).</li>
<li>De Koning, E. J., Bodkin, N. L., Hansen, B. C., Clark, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Diabetes+mellitus+in+Macaca+mulatta+monkeys+is+characterized+by+islet+amyloidosis+and+reduction+in+beta-cell+population%5BTitle%5D)+AND+%22Diabetologia%22%5BJournal%5D)">Diabetes mellitus in Macaca mulatta monkeys is characterized by islet amyloidosis and reduction in beta-cell population.</a> Diabetologia. 36, 378-384 (1993).</li>
<li>Letiexhe, M. R., Scheen, A. J., Gerard, P. L., Desaive, C., Lefebvre, P. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Insulin+secretion%2C+clearance+and+action+before+and+after+gastroplasty+in+severely+obese+subjects%5BTitle%5D)+AND+%22Int+J+Obes+Relat+Metab+Disord%22%5BJournal%5D)">Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects.</a> Int J Obes Relat Metab Disord. 18, 295-300 (1994).</li>
<li>Letiexhe, M. R., Scheen, A. J., Gerard, P. L., Desaive, C., Lefebvre, P. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Postgastroplasty+recovery+of+ideal+body+weight+normalizes+glucose+and+insulin+metabolism+in+obese+women%5BTitle%5D)+AND+%22J+Clin+Endocrinol+Metab%22%5BJournal%5D)">Postgastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women.</a> J Clin Endocrinol Metab. 80, 364-369 (1995).</li>
<li>Kim, S. H., Abbasi, F., Chu, J. W., McLaughlin, T. L., Lamendola, C., Polonsky, K. S., Reaven, G. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Rosiglitazone+reduces+glucose-stimulated+insulin+secretion+rate+and+increases+insulin+clearance+in+nondiabetic%2C+insulin-resistant+individuals%5BTitle%5D)+AND+%22Diabetes%22%5BJournal%5D)">Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals.</a> Diabetes. 54, 2447-2452 (2005).</li>
<li>Toffolo, G., Breda, E., Cavaghan, M. K., Ehrmann, D. A., Polonsky, K. S., Cobelli, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Quantitative+indexes+of+beta-cell+function+during+graded+up+and+down+glucose+infusion+from+C-peptide+minimal+models%5BTitle%5D)+AND+%22Am+J+Physiol+Endocrinol+Metab%22%5BJournal%5D)">Quantitative indexes of beta-cell function during graded up and down glucose infusion from C-peptide minimal models.</a> Am J Physiol Endocrinol Metab. 280, E2-E10 (2001).</li>
<li>Wang, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Quantification+of+beta-cell+insulin+secretory+function+using+a+graded+glucose-infusion+with+C-peptide+deconvolution+in+dysmetabolic%2C+and+diabetic+cynomolgus+monkeys%5BTitle%5D)+AND+%22Diabetology+and+Metabolic+Syn%22%5BJournal%5D)">Quantification of beta-cell insulin secretory function using a graded glucose-infusion with C-peptide deconvolution in dysmetabolic, and diabetic cynomolgus monkeys.</a> Diabetology and Metabolic Syn. 5, 40(2013).</li>
<li>Xiao, Y. F., Wang, B., Wang, X., Du, F., Benzinou, M., Wang, Y. X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Xylazine-induced+reduction+of+tissue+sensitivity+to+insulin+leads+to+acute+hyperglycemia+in+diabetic+and+normoglycemic+monkeys%5BTitle%5D)+AND+%22Anesthesiology%22%5BJournal%5D)">Xylazine-induced reduction of tissue sensitivity to insulin leads to acute hyperglycemia in diabetic and normoglycemic monkeys.</a> Anesthesiology. 13 (33), (2013).</li>
<li>Porte, D., Kahn, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((%CE%B2-cell+dysfunction+and+failure+in+type+2+diabetes+potential+mechanisms%5BTitle%5D)+AND+%22Diabetes%22%5BJournal%5D)">β-cell dysfunction and failure in type 2 diabetes potential mechanisms.</a> Diabetes. 50, Suppl 1. S160-S163 (2001).</li>
<li>DeFronzo, R. A., Tobin, J. D., Andres, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Glucose+clamp+technique%3A+a+method+for+quantifying+insulin+secretion+and+resistance%5BTitle%5D)+AND+%22American+Journal+of+Physiology%22%5BJournal%5D)">Glucose clamp technique: a method for quantifying insulin secretion and resistance.</a> American Journal of Physiology. 237 (3), G214-G223 (1979).</li>
<li>Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., DeFronzo, R. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((%CE%B2-cell+function+in+subjects+spanning+the+range+from+normal+glucose+tolerance+to+overt+diabetes%3A+a+new+analysis%5BTitle%5D)+AND+%22J+Clin+Endocrinol+Metab%22%5BJournal%5D)">β-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis.</a> J Clin Endocrinol Metab. 90 (1), 493-500 (2005).</li>
<li>Vaughan, K. L., Szarowicz, M. D., Herbert, R. L., Mattison, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Comparison+of+anesthesia+protocols+for+intravenous+glucose+tolerance+testing+in+rhesus+monkeys%5BTitle%5D)+AND+%22J+Med+Primatol%22%5BJournal%5D)">Comparison of anesthesia protocols for intravenous glucose tolerance testing in rhesus monkeys.</a> J Med Primatol. 43, 162-168 (2014).</li>
<li>Kemnitz, J. W., Kraemer, G. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Assessment+of+glucoregulation+in+rhesus+monkeys+sedated+with+ketamine%5BTitle%5D)+AND+%22American+Journal+of+Primatology%22%5BJournal%5D)">Assessment of glucoregulation in rhesus monkeys sedated with ketamine.</a> American Journal of Primatology. 3, 201-210 (1982).</li>
<li>Dutton, C. J., Parvin, C. A., Gronowski, A. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Measurement+of+glycated+hemoglobin+percentages+for+use+in+the+diagnosis+and+monitoring+of+diabetes+mellitus+in+nonhuman+primates%5BTitle%5D)+AND+%22Am+J+Vet+Res%22%5BJournal%5D)">Measurement of glycated hemoglobin percentages for use in the diagnosis and monitoring of diabetes mellitus in nonhuman primates.</a> Am J Vet Res. 64, 562-568 (2003).</li>
<li>Rai, V., Iyer, U., Mani, I., Mani, U. V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Serum+biochemical+changes+in+insulin+dependent+and+non-insulin+dependent+diabetes+mellitus+and+their+role+in+the+development+of+secondary+complications%5BTitle%5D)+AND+%22Int+J+Diab+Dev+Countries%22%5BJournal%5D)">Serum biochemical changes in insulin dependent and non-insulin dependent diabetes mellitus and their role in the development of secondary complications.</a> Int J Diab Dev Countries. 17, 33-37 (1997).</li>
<li>Shirasaki, Y., Yoshioka, N., Kanazawa, K., Maekawa, T., Horikawa, T., Hayashi, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Effect+of+physical+restraint+on+glucose+tolerance+in+cynomolgus+monkeys%5BTitle%5D)+AND+%22J+Med+Primatol%22%5BJournal%5D)">Effect of physical restraint on glucose tolerance in cynomolgus monkeys.</a> J Med Primatol. 42, 165-168 (2013).</li>
</ol>

The authors are affiliated with a contract research organization (Crown Bioscience) active in the field of metabolic disease.

The IVGTT assesses the capacity of glucose-stimulated insulin release by a single dextrose infusion based on body weight 5, 12, 13. From the assay, the fasting blood glucose and insulin level is attained, and it allows an assessment of the animal&#39;s capacity to release insulin and return the elevated glucose level towards baseline. This provides the user with information to characterize the animal as a normal glucose and insulin level healthy control, a hyperinsulinemic dysmetabolic animal with normoglycemi...

The IVGTT is a convenient functional assay that is routinely used to determine the &#946;-cell function in humans at different metabolic states 5, 7. In animal models of T2D, it is well recognized as a tool to characterize animals that show metabolic disease progression from a healthy to a dysmetabolic hyperglycemic state 8, 9. The closest animal model of T2D is demonstrated in nonhuman primates (NHPs), of which rhesus and cynomolgus macaques are notable examples. These animals naturally develop T2D with the same risk factors of age and obesity contributing to its incidence as in humans 10. Furthermore, there is a similar disease progression and pancreatic pathology showing amyloid deposits as the dysmetabolic disease progresses 11.
Here we report on our standard method of performing an IVGTT in NHPs as part of our colony characterization of metabolic status in these animals. This method is easy to perform relative to other, more time consuming and costly techniques 2. The IVGTT is useful for characterizing a large colony of animals rapidly and frequently. When taken into consideration with the level of glycated hemoglobin (HbA1C), the animal&#39;s diet and food intake history, as well as their percent lean mass and body fat, the IVGTT is normally sufficient for characterizing an animal&#39;s metabolic status and progression toward overt diabetes 6, 8.
HbA1C represents the average glycemic level over the life of a red blood cell, providing a reliable measure of glucose levels over the previous six weeks to three months. When measured from the fasted baseline blood sample of the IVGTT, this value provides a window into glycemic control during the months between procedures. If the animal has transitioned from dysmetabolic to diabetic since their last IVGTT, an HbA1C value much higher than their previous value would indicate that the transition began soon after their last IVGTT, whereas, an HbA1C value closer to their previous value would indicate that they have only recently transitioned. In general, in rhesus macaques, HbA1C values greater than 6% are considered abnormal, and indicate poor glycemic control 10, 23.
Glycemic levels should be interpreted within the context of the behavior and general health of the animal as a whole. Diabetic macaques &#8212; like humans &#8212; exhibit hyperphagia, polydipsia, and polyuria. Group housing of animals provides significant challenges to measurement of these indicators and the individual care required for dysmetabolic and diabetic monkeys. We recommend singly housing the animals in order that more personalized care may be provided, and behavioral markers of the health of the monkey more easily be monitored 8. Additionally, diabetic macaques will exhibit weight loss, as well as an elevated lipid profile (increased cholesterol, hypertriglyceridemia) and disturbed mineral metabolism in serum chemistry. It is important to measure markers of liver and kidney function in serum chemistry, as damage to these organs are often complications of advancing metabolic disorder/diabetes, and may be co-determinants of glycemic, lipid and mineral imbalances 9, 11, 18, 24.
When using this method, the historic values generated from multiple, frequent characterizations over the life of a monkey are of particular value. If other procedures, such as a glucose clamp or graded glucose infusion (GGI), are needed to fully assess an animal&#39;s health, it is commonly upon initial characterization when their history is unavailable. However, once a baseline has been established, repeated IVGTTs of a frequency of every three months are normally sufficient to track an animal&#39;s progress. This is particularly important when the animals are enrolled into multiple studies throughout a calendar year based upon their metabolic status. While their health may remain relatively stable for years at a time, when the metabolic status of an animal worsens, a dramatic increase in insulin resistance and glucose intolerance can occur very rapidly. HbA1C values allow for some interpolation of the decline or improvement of the health status of the animal between procedures scheduled three months apart. For this reason, this method is ideal for characterizing animals used in multiple, longitudinal studies over the course of their natural lifespan.

<table><tbody><tr><td>Allegra X-15R Centrifuge</td><td></td><td></td><td>plasma: 4 &amp;#176;C at 3,000 rpm for 10 min</td></tr><tr><td>Sorvall ST16R Centrifuge</td><td></td><td></td><td>serum: 22 &amp;#176;C at 3,000 rpm for 10 min</td></tr><tr><td>Thermo Scientific -86 &amp;#176;C Freezer, Forma 88000 Series</td><td></td><td>Model: 88500A</td><td></td></tr><tr><td>Dextrose 50% (D50)</td><td>Webster</td><td>07-8008986</td><td>I.V. glucose infusate</td></tr><tr><td>3 ml Luer Lock Syringe</td><td>Midwest Veterinary Suppy</td><td></td><td>serial blood draws</td></tr><tr><td>5 ml Luer Lock Syringe</td><td>Midwest Veterinary Suppy</td><td></td><td>heparinized saline flush</td></tr><tr><td>10 ml Luer Lock Syringe</td><td>Midwest Veterinary Suppy</td><td></td><td>delivery of I.V. D50</td></tr><tr><td>Gauze sponges 2 x 2</td><td>Midwest Veterinary Suppy</td><td>366.23000.4</td><td>Used Dry, w/ 70% Alcohol, and 2% Chlorohex Solution</td></tr><tr><td>4 ml serum separator tubes&amp;nbsp;</td><td>Midwest Veterinary Supply</td><td>366.45000.4</td><td>blood collection tube for superchem panel</td></tr><tr><td>K&lt;sub&gt;2&lt;/sub&gt;EDTA, 2 ml</td><td>VWR</td><td>95057-239</td><td>blood collection tubes</td></tr><tr><td>Aprotinin, 100 mg</td><td>Sigma</td><td>A1153-100MG</td><td>blood collection tube protease additive</td></tr><tr><td>22 G x 1&quot; Catheters</td><td>Midwest Veterinary Suppy</td><td>193.75250.2</td><td>I.V. catheter&amp;nbsp;</td></tr><tr><td>Injection Plug W/ Cap</td><td>Midwest Veterinary Suppy</td><td>001.11500.2</td><td>%50 dextrose infusion port</td></tr><tr><td>Porus Tape, 1/2&quot; x 10 yd</td><td>Midwest Veterinary Suppy</td><td>001.85000.2</td><td>maintain adherance of catheters and hep. Locks</td></tr><tr><td>Chlorhexidine Solution 2%</td><td>Midwest Veterinary Suppy</td><td>193.08855.3</td><td>prep catheter site</td></tr><tr><td>70% Ethanol</td><td>VWR</td><td>71001-654</td><td>prep catheter site</td></tr><tr><td>tourniquet</td><td>Webster</td><td>07-8003432</td><td></td></tr><tr><td>3-way stopcock</td><td>Midwest Veterinary Supply</td><td>366.28510.4</td><td>hep. lock</td></tr><tr><td>37&quot; extension set</td><td>Webster</td><td>07-8454200</td><td>hep. lock</td></tr><tr><td>Exel 50-60cc LL Syringes</td><td>Midwest Veterinary Suppy</td><td>001.12250.2</td><td>Heparinized saline flush</td></tr><tr><td>250 ml bag 0.9% saline</td><td>Webster</td><td>07-8365593</td><td>flush</td></tr><tr><td>1,000 U Heparin, 10 ml</td><td>Webster</td><td>07-883-4916</td><td></td></tr><tr><td>Ketamine (Ketaset) 100&amp;nbsp;mg/ml</td><td>Fort Dodge</td><td>(AV ordered)</td><td></td></tr><tr><td>Precision Xtra glucose test strips 50/bx</td><td>Abbott (American Diabetes Wholesale)</td><td>9381599728K7</td><td>test baseline/T3 blood glucose levels</td></tr><tr><td>Masimo Rad 57</td><td>DRE</td><td>6052057V</td><td>pulse-oximeter</td></tr><tr><td>Pavia rectal thermometer</td><td>Patterson</td><td>07-8391335</td><td></td></tr><tr><td>Precision Xtra Glucometer</td><td>Abbott</td><td>9381599728K7</td><td>Handheld glucometer</td></tr></tbody></table>

characterization of metabolic status in nonhuman primates with the intravenous glucose tolerance test

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

The intravenous glucose tolerance test (IVGTT) plays a key role in the characterization of glucose homeostasis. When taken together with serum biochemical profiles, inclusive of blood glucose levels in both the fed and fasted state, HbA1c, insulin levels, clinical history of diet, body composition, and body weight status, an assessment of normal and abnormal glycemic control can be made. Interpretation of an IVGTT is done through measurement of changes in glucose and insulin levels over time in relation to the dextrose challenge. Critical components to be considered are: peak glucose and insulin levels reached in relation to T0 (end of glucose infusion), the glucose clearance rate K derived from the slope of rapid glucose clearance in the first 20 min (T1 to T20), the time to return to glucose baseline, and the area under the curve (AUC). These IVGTT measures will show characteristic changes as glucose homeostasis moves from a healthy to a diseased metabolic state5. Herein we will describe the characterization of nonhuman primates (Rhesus and Cynomolgus macaques), which are the most relevant animal model of Type II diabetes (T2D) in humans and the IVGTT and clinical profiles of these animals from a lean healthy, to obese dysmetabolic, and T2D state 8, 10, 11.

The results shown in Figure 1 are demonstrative of typical glucose and insulin curves from mature, healthy and diabetic cynomolgus macaques over the course of a 30 min IVGTT. Data from healthy and advanced diabetic monkeys are shown in order to contrast the obvious differences between animals from both extreme ends of the range of metabolic characterization. This IVGTT protocol has been used successfully by the authors in rhesus macaques with similar results.
<p class...

The goal of this protocol is to present a standard method to perform intravenous glucose tolerance tests (IVGTTs) to assess glycemic control in nonhuman primates and assess their metabolic status from healthy to dysmetabolic.

The intravenous glucose tolerance test (IVGTT) plays a key role in the characterization of glucose homeostasis. When taken together with serum biochemical ...

The overall goal of this intravenous glucose tolerance test, or IVGTT, is to characterize the progression of metabolic disease in macaques, from a healthy to a dismetabolic, hyperglycemic state. This method can be used to establish cohorts of subjects stratified by their metabolic status for dietary or pharmacological investigation of the therapeutic efficacy of treatments for insulin resistance in diabetes. The main advantage of this technique is that it is easy to perform relative to other more time consuming and costly techniques.14 to 18 hours before beginning the procedure, remove the food from the macaque's cage to avoid any post-prandial variegation in the glycemic values. The next morning, weigh the sedated animal. Then place the primate in a laterally recumbent position on a heated procedure table.Every 15 to 20 minutes, use a pulse oximeter to measure the heart rate and peripheral capillary oxygen saturation. Use a stop watch to measure the respiratory rate, and a thermometer to measure the temperature rectally. Confirm that the mucous membrane around the gum and lips is moist and pink at every clinic parameter check as well.After confirming the baseline health of the animal, use clippers to trim the hair from the areas where the catheters will be inserted, followed by the sterilization of both regions with alternating scrubs of chlorhexidine and 70%alcohol. When the sites are ready, insert the first catheter and attach the lure to a heparin-saline flush with a three-way stopcock. This is the sampling blood draw site.Tape the stopcock to secure it to the leg. The placement of the catheter is critical for patency and precise serial blood draws. Therefore, it is important to consider a medial and more proximal region of the saphenous vein to easily secure and manipulate the heparinized flush in-lock system.Then, place the second catheter, and attach a port for the dextrose infusion, followed by the administration of a one millilitre flush of heparinized saline to keep the cannula patent until the dextrose infusion. Tape the port to the arm to secure it. When both of the catheters are in place, obtain a baseline sample, and use a handheld glucometer to measure the fasting blood glucose level.Secure a serum sample for the standard chemistry analysis, as well as a whole blood sample for a complete blood cell count to assess the overall health of the animal. Invert the whole blood sample. After each blood draw, mix the samples in EDTA tubes with the protease inhibitors.After obtaining the baseline samples, infuse the 50%dextrose dose over 30 seconds via the dextrose infusion port. Then, flush with five milliliters of heparinized saline, so that no dextrose is left in the port. At the end of the infusion, change gloves, as residual dextrose from the infusion may contaminate the subsequent blood samples.The first post-infusion sample time point is at time three minutes from the end of the dextrose infusion, followed by samples at T five, seven, 10, 15, and 20 minutes, with the last sample obtained at T 30 minutes. Centrifuge the samples for glucose and insulin analysis within 10 minutes of collection, then aliquot the plasma into cryovials for freezing and storage at negative 80 degrees Celsius, until downstream analysis of the samples. At the T three sample draw, use the handheld glucometer to check the blood glucose level for confirmation of the dextrose infusion.When the last sample has been collected, remove the cannulas, applying pressure to the catheterized sites for hemostasis, and monitor the animal until it is fully recovered. Here, typical glucose and insulin curves from mature, healthy and diabetic cynomolgus macaques over the course of a 30 minute IVGTT are shown. The fasted baseline glucose values of healthy macaques can be as low as 50 to 60 milligrams per deciliter, with an initial plasma glucose spike observed at the T three minute time point.That is dramatically lower than the typical plasma glucose spike exhibited by diabetic animals. Over the course of the procedure, the glucose levels of healthy animals often return to their baseline values, while dismetabolic and diabetic animal levels do not. The accompanying insulin curve for a healthy animal exhibits two peaks, corresponding to an initial rapid decline in blood glucose mediated in larger than normal part by the peripheral effects of insulin on glucose transport and uptake.The magnitude of these peripheral effects, even during the first phase of the insulin response, does not equal the contribution of the liver to glucose lowering, which, during the smaller but more sustained second insulin peak, has the greatest impact on glycemic levels via the suppression of endogenous glucose production. Once an animal has become overly diabetic, insulin production in response to the dextrose bolus drops dramatically. Glycemic levels will remain elevated over the course of the procedure.As with glucose, clearance occurs is now mediated almost entirely by non-insulin dependent mechanisms. Following this procedure, other methods like graded glucose infusion, or the hyperinsulinemic euglycemic clamp can be performed to answer additional questions about insulin sensitivity. Don't forget that working with needles exposed to macaque blood can be extremely hazardous, due to the potential for exposure to herpes B virus.Precautions, such as wearing the proper personal protective gear, and taking extreme care when handling sharps should always be observed while performing this procedure.

characterization-metabolic-status-nonhuman-primates-with-intravenous

Research

JoVE Journal

Medicine

The hyperinsulinemic-euglycemic clamp, or insulin clamp, is the gold standard for assessing insulin action in vivo.  A method for performing insulin clamps in mice is described.  This includes a method for arterial catheterization that permits experiments to be performed in conscious, unrestrained mice with minimal stress.

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

This video introduces how to perform an oral glucose tolerance test on a laboratory mouse.

Oral Glucose Tolerance Test (OGTT): Measuring Glucose Metabolism in Mice

The current article describes the generation and metabolic characterization of high-fat diet-fed mice as a model of diet-induced insulin resistance and obesity. It further features detailed protocols to perform the oral glucose tolerance test and the insulin tolerance test, monitoring whole-body alterations of glucose metabolism in vivo.

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

The incidence of obesity is rising and increases the risk of chronic lung diseases. To establish the underlying mechanisms and preventive strategies, well-defined animal models are needed. Here, we provide three methods (glucose-tolerance-test, body plethysmography, and lung fixation) to study the effect of obesity on pulmonary outcomes in mice.

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

This protocol describes the use of a body composition analyzer and metabolic animal monitoring system to characterize body composition and metabolic parameters in mice. An obesity model induced by high-fat feeding is used as an example for the application of these techniques.

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

The current article describes a detailed protocol for isocaloric 2:1 intermittent fasting to protect and treat against obesity and impaired glucose metabolism in wild-type and ob/ob mice.

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice

This protocol demonstrates the accurate and reproducible measurement of oxygen consumption in non-human primate pancreatic islets. The islet loading techniques and coating of the microplate provide a framework for efficient measurement of respiration in other types of cultured spheroids.

Analysis of Non-Human Primate Pancreatic Islet Oxygen Consumption

This study describes the direct measurement of hepatic glucose production in a polycystic ovary syndrome mouse model by using a stable isotopic glucose tracer via tail vein in both fasting and glucose-rich states in tandem.

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Here, we present a protocol to quantify the physiological significance of the impact of brown adipose tissue (BAT) activity on human metabolism. This is achieved by combining carbohydrate loading and indirect calorimetry with measurements of supraclavicular changes in temperature. This novel approach can help develop a pharmacological target for BAT thermogenesis in humans.

Using a Combination of Indirect Calorimetry, Infrared Thermography, and Blood Glucose Levels to Measure Brown Adipose Tissue Thermogenesis in Humans

A test battery (IMAP) for performing an in-depth assessment of auditory and cognitive abilities contributing to listening skills is described. It is quick to administer, child-friendly and free from linguistic confounds. Stimulus generation and protocol management are controlled via a software platform (IHR-STAR) to ensure replicable procedures.

Making Sense of Listening: The IMAP Test Battery

Learn to perform intravenous glucose tolerance tests in macaques for metabolic disease research. This standardized protocol enables stratification of subjects by glycemic status to study insulin resistance and diabetes progression.

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Explore More Videos